NCT01020123

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 530 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

Conditions

• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	AZD1656	Different doses of AZD1656 administered to 5 groups of patients
DRUG	Placebo	AZD1656 placebo and glipizide placebo administered to 1 group of patients
DRUG	Glipizide	Glipizide administered to 1 group of patients

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2009-11-25
• Last updated: 2012-11-26
• Results posted: 2012-11-26

Locations

77 sites across 11 countries: Chile, Germany, Hungary, Latvia, Lithuania, Mexico, Peru, Poland, Romania, Sweden, United Kingdom